Maitreyee Hazarika - Concepedia

Author

Maitreyee Hazarika

Also Known As

M. Hazarika, Maitreyee Hazarika

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Maitreyee Hazarika is an author at Center for Drug Evaluation and Research specializing in oncology, medicine, and drug resistance.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	182
2	Immunology	1	1	172
3	Pathology	1	1	10
4	Pharmacology	1	1	10
5	Cancer Therapeutics	1	1	10

Maitreyee Hazarika

Publications

721

Citations

H-Index

Page 1

	Year	Citations
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret, Clinical Cancer Research	2017	181
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey, The Lancet Oncology Cancer ImmunosurveillanceMedicineRecist ProgressionImmunologyMelanoma	2018	172
Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib Maitreyee Hazarika, Xiaoping Jiang, Qi Liu, Clinical Cancer Research	2008	134
Pemetrexed in Malignant Pleural Mesothelioma Maitreyee Hazarika, Robert M. White, Brian Booth, Clinical Cancer Research	2005	109
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma Amy Barone, Maitreyee Hazarika, Marc R. Theoret, Clinical Cancer Research	2017	86
Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy Maitreyee Hazarika, Edwin P. Rock, Gene M. Williams, The Oncologist	2008	29
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days Franco M. Muggia, Leonard Liebes, Maitreyee Hazarika, Anti-Cancer Drugs Molecular PharmacologyTranslational PharmacologyOncologyMedicinePlasma Auc Ratio	2002	10

Page 1